Amgen Ruling Could Prevent Slowdowns in Biosimilar Market Entry

Published July 6, 2020

Changes to a biosimilar’s manufacturing locations or labels won’t be enough for innovator biotech companies to block a competitor from bringing their drug to market following a Federal Circuit ruling in a case over an Amgen Inc. cancer drug.